EUCTR2011-005154-57-FR进行中（未招募）不适用
An open-label extension study to assess efficacy, safety and tolerability of canakinumab and the efficacy and safety of childhood vaccinations in patients with Cryopyrin Associated Periodic Syndromes (CAPS) - D2307E1
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patients who completed the core CACZ885D2307 study (a patient is defined as having completed the core study if they completed the study up to and including the EOS visit with no major protocol deviations in the core).
- •2.Male and female patients that are = 1 year of age at the time of the roll-over visit.
- •3.Parent or legal guardian written informed consent must be obtained before any assessment in the extension CACZ885D2307E1 study is performed.
- •Other protocol-defined inclusion/exclusion criteria may apply
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 16
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patients for whom continued treatment in the CACZ885D2307E1 extension study is not considered appropriate by the treating physician.
- •2.Patients who discontinued from the core CACZ885D2307 study.
- •Other protocol-defined inclusion/exclusion criteria may apply
研究者
相似试验
进行中（未招募）
1 期
A study to check how safe, beneficial and tolerable the drug canakinumab, along with childhood vaccines, is for patients with crypoyrin associated periodic syndromes (CAPS).EUCTR2011-005154-57-BEovartis Pharma Services AG16
进行中（未招募）
不适用
An extension study to check how safe, beneficial and tolerable the drugcanakinumab, along with childhood vaccines, is for patients with crypoyrin associated periodic syndromes (CAPS).EUCTR2011-005154-57-ESovartis Farmacéutica S.A16
进行中（未招募）
1 期
A study to check how safe, beneficial and tolerable the drug canakinumab, along with childhood vaccines, is for patients with crypoyrin associated periodic syndromes (CAPS).Cryopyrin Associated Periodic Syndromes (CAPS)MedDRA version: 17.0 Level: PT Classification code 10068850 Term: Cryopyrin associated periodic syndrome System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-005154-57-GBovartis Pharma Services AG17
进行中（未招募）
不适用
A study to check how safe, beneficial and tolerable the drug canakinumab, along with childhood vaccines, is for patients with crypoyrin associated periodic syndromes (CAPS).Cryopyrin Associated Periodic Syndromes (CAPS)MedDRA version: 14.1Level: PTClassification code 10068850Term: Cryopyrin associated periodic syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-005154-57-DEovartis Pharma Services AG16
尚未招募
2 期
An open-label extension study to investigate efficacy, safety and tolerability of LTP001 in participants with pulmonary arterial hypertensioNL-OMON53913ovartis3